# Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting

> **NCT06639620** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 250 (actual)

## Conditions studied

- Advanced Parkinson Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06639620
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06639620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06639620, "Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06639620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*